



## **NORGINE'S PETER MARTIN ELECTED TO ABPI BOARD OF MANAGEMENT**

28 April 2005

Peter Martin, Norgine's Chief Operating Officer was elected this month to The Association of the British Pharmaceutical Industry (ABPI) Board of Management.

Mr Martin joined Norgine, an independent, successful European specialty pharmaceutical company, in May last year. Norgine has been established for almost 100 years and has a presence in all the major European markets. In 2004 Norgine's sales were €156 million, the 18<sup>th</sup> consecutive year of double-digit growth. The company employs 900 people, of which 350 are in sales and marketing.

**ENDS**

### **Notes to editor**

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. Movicol® for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy, Fivasa® for the treatment of inflammatory bowel disease and Oramorph® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has nine products at various stages of clinical development including NRL994, a bowel preparation product. A European submission for NRL994 has already been filed and the company expects to submit an NDA in 2005.

Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is [www.norgine.com](http://www.norgine.com)

**For further information, please contact:**

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: [ppay@norgine.com](mailto:ppay@norgine.com)

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: [lblakeborough@chapterfive.co.uk](mailto:lblakeborough@chapterfive.co.uk)